• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Hernandez Laurie converted options into 1,723 shares, increasing direct ownership by 91% to 3,608 units (SEC Form 4)

    5/13/25 7:42:03 PM ET
    $ICUI
    Medical/Dental Instruments
    Health Care
    Get the next $ICUI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Hernandez Laurie

    (Last) (First) (Middle)
    951 CALLE AMANECER

    (Street)
    SAN CLEMENTE CA 92673

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    ICU MEDICAL INC/DE [ ICUI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/13/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock(1) 05/13/2025 M 1,723 A $0.0 3,608 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Stock(1) $0.0(2) 05/13/2025 M 1,723 05/15/2025(3) 05/15/2025 Common Stock 1,723 $0.0 0 D
    Common Stock(1) $0.0(2) 05/13/2025 A 1,254 05/13/2026(3) 05/13/2026 Common Stock 1,254 $0.0 1,254 D
    Explanation of Responses:
    1. These securities are Restricted Stock Units.
    2. There is neither a purchase price nor an exercise price for the Restricted Stock Units.
    3. These awards vest on the anniversary of the date of the grant or the following annual stockholder meeting, whichever occurs first.
    By: Paula Darbyshire, Attorney-in-Fact For: Laurie Hernandez 05/13/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ICUI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ICUI

    DatePrice TargetRatingAnalyst
    3/12/2025$205.00 → $197.00Outperform → Strong Buy
    Raymond James
    12/11/2024$200.00Hold → Buy
    Jefferies
    10/14/2024$183.00Hold
    Jefferies
    6/21/2024Hold
    Needham
    6/17/2024$135.00Mkt Perform → Outperform
    Raymond James
    11/8/2022Outperform → Mkt Perform
    Raymond James
    2/28/2022$286.00 → $265.00Outperform
    Raymond James
    10/22/2021$302.00 → $280.00Overweight
    Keybanc
    More analyst ratings

    $ICUI
    Leadership Updates

    Live Leadership Updates

    See more
    • Carlyle Group and WP Carey Set to Join S&P MidCap 400; Others to Join S&P SmallCap 600

      NEW YORK, Nov. 27, 2023 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 effective prior to the open of trading on Thursday, November 30: Carlyle Group Inc. (NASD: CG) will replace ICU Medical Inc. (NASD: ICUI) in the S&P MidCap 400. ICU Medical will replace PacWest Bancorp (NASD: PACW) in the S&P SmallCap 600. Banc of California Inc. (NYSE:BANC) is acquiring PacWest Bancorp in a deal expected to be completed soon, pending final closing conditions. Post-merger, Banc of California will remain in the S&P SmallCap 600. ICU Medical is more representative of the small-cap market space.WP Carey Inc. (NYSE: WPC) will replace Worthingt

      11/27/23 6:28:00 PM ET
      $AVTA
      $BANC
      $CG
      $CWEN
      Finance: Consumer Services
      Finance
      Major Banks
      Investment Managers

    $ICUI
    SEC Filings

    See more
    • ICU Medical Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

      5/14/25 2:49:34 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by ICU Medical Inc.

      10-Q - ICU MEDICAL INC/DE (0000883984) (Filer)

      5/8/25 5:06:47 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ICU MEDICAL INC/DE (0000883984) (Filer)

      5/8/25 4:08:03 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Financials

    Live finance-specific insights

    See more
    • ICU Medical Announces First Quarter 2025 Results

      SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

      5/8/25 4:05:00 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Announces Time of First Quarter 2025 Earnings Conference Call

      SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2025 earnings release and conference call. The Company will release its first quarter 2025 results on Thursday, May 8, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 8, 2025. The call can be accessed at (800) 225-9448, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's webs

      4/24/25 8:30:00 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Announces Fourth Quarter 2024 Results and Provides Fiscal Year 2025 Guidance

      SAN CLEMENTE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended December 31, 2024. Fourth Quarter 2024 Results Fourth quarter 2024 revenue was $629.8 million, as compared to $587.9 million in the same period in the prior year. GAAP gross profit for the fourth quarter of 2024 was $227.3 million, as compared to $171.6 million in the same period in the prior year. GAAP gross margin for the fourth quarter of 2024 was 36.1%, as compared to 29.2% in the same period in the prior year. GAAP net loss for the fourth quarter of 2

      2/27/25 4:05:00 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ICU Medical Announces First Quarter 2025 Results

      SAN CLEMENTE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced financial results for the quarterly period ended March 31, 2025. First Quarter 2025 Results First quarter 2025 revenue was $604.7 million, as compared to $566.7 million in the same period in the prior year. GAAP gross profit for the first quarter of 2025 was $210.1 million, as compared to $185.2 million in the same period in the prior year. GAAP gross margin for the first quarter of 2025 was 35%, as compared to 33% in the same period in the prior year. GAAP net loss for the first quarter of 2025 was $(15.

      5/8/25 4:05:00 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical, Inc. and Otsuka Pharmaceutical Factory, Inc. Complete Joint Venture to Bolster IV Solutions Manufacturing and Innovation in North America

      The partnership creates one of the largest global IV solutions manufacturing networks with combined production of an estimated 1.4 billion annual units and aims to bring additional supply chain resiliency and new innovation to the North American IV solutions market. SAN CLEMENTE, Calif. and TOKUSHIMA, Japan, May 1, 2025 /PRNewswire/ -- ICU Medical, Inc. (NASDAQ:ICUI), a worldwide leader in the development, manufacture and sale of innovative medical devices, and Otsuka Pharmaceutical Factory, Inc. (OPF), a subsidiary of Otsuka Holdings Co., Ltd. engaged in the global manufacturing and sale of IV solutions, together announce the formation of Otsuka ICU Medical LLC—a new joint venture aimed at

      5/1/25 8:30:00 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical Announces Time of First Quarter 2025 Earnings Conference Call

      SAN CLEMENTE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (NASDAQ:ICUI), a leader in the development, manufacture and sale of innovative medical products, today announced the time of its first quarter 2025 earnings release and conference call. The Company will release its first quarter 2025 results on Thursday, May 8, 2025 at approximately 4:00 p.m. ET (1:00 p.m. PT) and will be conducting a conference call concerning those results at 4:30 p.m. ET (1:30 p.m. PT) on Thursday, May 8, 2025. The call can be accessed at (800) 225-9448, conference ID "ICUMED". The conference call will be simultaneously available by webcast, which can be accessed by going to the Company's webs

      4/24/25 8:30:00 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Voigtlander Christian B. sold $1,523,301 worth of shares (11,111 units at $137.10) and exercised 11,111 shares at a strike of $96.83 (SEC Form 4)

      4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

      5/15/25 4:57:09 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Chief Information Officer Sousa Ben sold $274,714 worth of shares (2,000 units at $137.36), decreasing direct ownership by 81% to 479 units (SEC Form 4)

      4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

      5/15/25 4:55:39 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Director Finney Elisha W converted options into 1,723 shares, increasing direct ownership by 81% to 3,852 units (SEC Form 4)

      4 - ICU MEDICAL INC/DE (0000883984) (Issuer)

      5/14/25 11:02:16 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

      SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

      11/12/24 3:44:43 PM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ICU Medical Inc.

      SC 13G/A - ICU MEDICAL INC/DE (0000883984) (Subject)

      11/8/24 10:34:33 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by ICU Medical Inc.

      SC 13D/A - ICU MEDICAL INC/DE (0000883984) (Subject)

      7/18/24 7:06:07 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER issued to ICU MEDICAL INC

      Submission status for ICU MEDICAL INC's drug POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER (SUPPL-8) with active ingredient POTASSIUM CHLORIDE; SODIUM CHLORIDE has changed to 'Approval' on 05/15/2023. Application Category: ANDA, Application Number: 078446, Application Classification: Labeling

      5/17/23 4:40:03 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care

    $ICUI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ICU Medical upgraded by Raymond James with a new price target

      Raymond James upgraded ICU Medical from Outperform to Strong Buy and set a new price target of $197.00 from $205.00 previously

      3/12/25 7:28:15 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • ICU Medical upgraded by Jefferies with a new price target

      Jefferies upgraded ICU Medical from Hold to Buy and set a new price target of $200.00

      12/11/24 7:52:44 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care
    • Jefferies initiated coverage on ICU Medical with a new price target

      Jefferies initiated coverage of ICU Medical with a rating of Hold and set a new price target of $183.00

      10/14/24 7:34:44 AM ET
      $ICUI
      Medical/Dental Instruments
      Health Care